| Budget Amount *help |
¥17,810,000 (Direct Cost: ¥13,700,000、Indirect Cost: ¥4,110,000)
Fiscal Year 2022: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2021: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2020: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2019: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2018: ¥8,060,000 (Direct Cost: ¥6,200,000、Indirect Cost: ¥1,860,000)
|
|---|
| Outline of Final Research Achievements |
Regarding detection of drug interactions and discovery of adverse events using real world data (RWD), we developed a gold standard that covers adverse events consisting of 92 types of positive and negative control pairs. As a result of evaluating whether early detection of adverse events is possible by applying association rule mining to medical receipts, we succeeded in detecting adverse event signals earlier than conventional methods even when using monthly receipt data. For the prediction of the receptor affinity of compounds, we normalized the chemical structures and affinity data for 1.71 million compounds, applied machine learning to the relationship between chemical structural formulas and receptor affinity, and succeeded in predicting affinity for new chemical structures.
|
